A STAT inhibitor patent review: Progress since 2011

Expert Opinion on Therapeutic Patents

Volumn 25, Issue 12, 2015, Pages 1397-1421

  Lai, Ping Shan ^a   Rosa, David A ^a   Magdy Ali, Ahmed ^a   Gómez Biagi, Rodolfo F ^a   Ball, Daniel P ^a   Shouksmith, Andrew E ^a   Gunning, Patrick T ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

anti cancer drugs; cancer therapeutics; JAK STAT pathway; molecular therapeutics; oncogene; protein protein interactions; signal transducer and activator of transcription 3 (STAT3)

Indexed keywords

3 (6 BROMO 2 PYRIDINYL) 2 CYANO N (1 PHENYLETHYL)ACRYLAMIDE; 4 AMINOBENZOIC ACID DERIVATIVE; 4 [[(4 METHYLPHENYL)SULFONYLOXY]ACETAMIDO]SALICYLIC ACID; AMINOSALICYLIC ACID; ANTHRAQUINONE DERIVATIVE; ANTINEOPLASTIC AGENT; CELECOXIB; CURCUMIN; DASATINIB; EPIGALLOCATECHIN GALLATE; FEDRATINIB; FLAVONOID; ISS 610; NSC 42067; NSC 59263; PEPTIDE; PEPTIDOMIMETIC AGENT; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SALICYLIC ACID DERIVATIVE; STAT INHIBITOR; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; STAT5A PROTEIN; STAT5B PROTEIN; SULFONAMIDE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; STAT5 PROTEIN;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER THERAPY; CARBOXY TERMINAL SEQUENCE; CLINICAL TRIAL (TOPIC); COMPLEX FORMATION; CYTOTOXICITY; DIMERIZATION; DRUG INDUSTRY; DRUG POTENCY; GLIOBLASTOMA CELL LINE; HUMAN; IC50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DOCKING; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHUMAN; PATENT; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DESIGN; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PATENTS AS TOPIC; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR;

EID: 84951574260     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2015.1086749     Document Type: Review

References (118)

1. Akira S. Functional roles of STAT family proteins: lessons from knockout mice. Stem Cells 1999;17:138-46
2. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T Lymphocytes. Nature 1996;383:787-93
3. Durbin JE, Hackenmiller R, Simon MC, Levy DE. Targeted disruption of the mouse STAT1 gene results in compromised innate immunity to viral disease. Cell 1996;84:443-50
4. Ramana CV, Chatterjee-Kishore MG, Nguyen HJ, Stark GG. Complex roles of STAT1 in regulating gene expression. Oncogene 2000;19:2619-27
5. Wakao H, Gouilleux F, Groner B. Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response. EMBO J 1994;13:2182-91
6. Hodge DR, Xiao W, Wang LH, et al. Activating mutations in STAT3 and STAT5 differentially affect cellular proliferation and apoptotic resistance in multiple myeloma cells. Cancer Bio Ther 2004;3:188-94
7. O'Sullivan LA, Liongue C, Lewis RS, et al. Cytokine receptor signaling through the JAK - STAT - Socs pathway in disease. Mol Immunol 2007;44:2497-506
8. Chung CD, Bin J, Rao X, et al. Specific inhibition of STAT3 signal transduction by PIAS3. Science 1997;278:1803-5
9. Haspel RL, Salditt-Georgieff M, Darnell JE. The rapid inactivation of nuclear tyrosine phosphorylated STAT1 depends upon a protein tyrosine phosphatase. EMBO J 1996;15:6262-8
10. Shuai K, Liao J, Song MM. Enhancement of antiproliferative activity of gamma interferon by the specific inhibition of tyrosine dephosphorylation of STAT1. Mol Cell Biol 1996;16:4932-41
11. Marotta LLC, Almendro V, Marusyk A, et al. The JAK2/STAT3 signaling pathway is required for growth of CD44 (+)CD24(-) stem cell-like breast cancer cells in human tumours. J Clin Invest 2011;121:2723-35
12. Zhao SH, Zhao F, Zheng JY, et al. Knockdown of STAT3 expression by RNAi inhibits in vitro growth of human ovarian cancer. Radiol Oncol 2011;45:196-203
13. Gu L, Dagvadorj A, Lutz J, et al. transcription factor STAT3 stimulates metastatic behaviour of human prostate cancer cells in vivo, whereas STAT5b has a preferential role in the promotion of prostate cancer cell viability and tumour growth. Am J Path 2010;176:1959-72
14. Song LX, Rawal B, Nemeth JA, Haura EB. JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6-neutralizing antibodies can suppress JAK1/STAT3 signaling. Mol Cancer Ther 2011;10:481-94
15. Corcoran RB, Contino G, Deshpande V, et al. STAT3 plays a critical role in KRAS-induced pancreatic tumourigenesis. Cancer Res 2011;71:5020-9
16. Levy DE, James E, Darnell J. STATs: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002;3:651-62.
17. John S, Vinkemeier U, Soldaini E, et al. The significance of tetramerization in promoter recruitment by STAT5. Mol Cell Biol 1999;19:1910-18
18. Chen X, Vinkemeier U, Zhao Y, et al. Crystal structure of a tyrosine phosphorylated STAT1 dimer bound to DNA. Cell 1998;93:827-39
19. Becker S, Groner B, Muller CW. Three-dimensional structure of the STAT3b homo-dimer bound to DNA. Nature 1998;394:145-51.
20. Gouilleux F, Wakao H, Mundt M, Groner B. A Prerequisite for DNA binding and induction of transcription. EMBO J 1994;13:4361-9
21. Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 2002;285:1-24
22. Hennighausen L, Robinson GW. Interpretation of cytokine signaling through the transcription factors STAT5a and STAT5b. Genes and Dev 2008;22:711-21
23. Ihle JN. The STAT family in cytokine signaling. Curr Opin Cell Biol 2001;13:211-17
24. Chen J, Sadowski HB, Kohanski RA, Wang L-H. Atat5 is a physiological substrate of the insulin receptor. Proc Natl Acad Sci USA 1997;94:2295-300
25. Valgeirsdottir SD, Paukku K, Silvennoinen O, et al. Activation of STAT5 by platelet-derived growth factor (PDGF) dependent on phosphorylation site in PDGF B-receptor juxtamembrane and kinase insert domains. Oncogene 1998;16:505-15
26. David M, Wong L, Flavell R, et al. STAT activation by epidermal growth factor (EGF) and amphiregulin. J Biol Chem 1996;271:9185-8
27. Welte T, Leitenberg D, Dittel BN, et al. STAT5 interaction with the T-cell receptor complex and stimulation of T-cell proliferation. Science 1999;283:222-5
28. Moriggl R, Gouilleux-Gruart V, Jahne R, et al. Deletion of the carboxyl-terminal transactivation domain of MGF-STAT5 results in sustained DNA binding and a dominant negative phenotype. Mol Cell Biol 1996;16:5691-70
29. Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF-Kappa B collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 2010;21:11-19
30. Page BDG, Ball DP, Gunning PT. Signal transducer and activator of transcription 3 inhibitors: a patent review. Expert Opin Ther Patents 2011;21:65-83
31. Lavecchia A, Giovanni CD, Cerchia C. Novel inhibitors of signal transducer and activator of transcription 3 signaling pathway: an update on the recent patent literature. Expert Opin Ther Patents 2014;24:383-400
32. Brantley EC, Nabors LB, Gillespie GY. Loss of protein inhibitors of activated of STAT3 expression in glioblastoma multiforme tumours: implications for STAT3 activation and gene expression. Clin Cancer Res 2008;14:4694
33. Ogata Y, Osaki T, Naka T, et al. Overexpression of PIAS3 suppresses cell growth and restores the drug sensitivity of human lung cancer cells in association with PI3-K/Akt inactivation. Neoplasia 2006;8:817-25
34. Yagil Z, Kay G, Nechushtan H, Razin E. A specific epitope of protein inhibitor of activated STAT3 is responsible for the induction of apoptosis in rat transformed mast cells. J Immunol 2009;182:2168-75
35. Wible BA, Wang L, Kuryshev YA, et al. Increased K+ efflux and apoptosis induced by the potassium channel modulatory protein KChAP/PIAS3 in prostate cancer cells. J Biol Chem 2002;277:17852-62
36. Heinz C, Groner B, Weber A. STAT3 activation inhibitors: Georg-Seyer-Haus Chemotherapeutisches Forschungsinstitut. WO 110359 A1; 2011
37. Borghouts C, Tittmann H, Delis N, et al. The intracellular delivery of a recombinant peptide derived from the acidic domain of PIAS3 inhibits STAT3 transactivation and induces tumour cell death. Mol Cancer Res 2010;8:539-53
38. Tarasova NI, Trinchieri G, Young HA, et al. Peptide-based inhibitor of interleukin-10 or interferon-gamma signaling: department of health and human services, USA. WO 143280 A2; 2011
39. Ren Z, Cabell LA, Schaefera TS, McMurray JS. Identification of a highaffinity phosphopeptide inhibitor of STAT3. Bioorg Med Chem Lett 2003;13:633-6
40. McMurray JS, Ren Z, David R, et al. Inhibitors of signal transducer and activator of transcription 3. US 0010428 A1; 2007
41. Wang S, Chen J, Zhao Y, et al. STAT3 inhibitors and therapeutic methods using the same: the Regents of the University of Michigan Office of Technology Transfer. WO 077589 A2; 2010
42. Chen J, Bai L, Bernard D, et al. Structure-based design of conformationally constrained, cell-permeable STAT3 inhibitors. Med Chem Lett 2010;1:85-9
43. McMurray JS, Mandal PK, Liao WS, et al. Inhibitors of STAT3 and uses thereof. board of regent of the university of texas system. US 0035114 A1; 2012
44. Mandal PK, Gao F, Lu Z, et al. Potent and selective phosphopeptide mimetic prodrugs targeted to the src homology 2 (SH2) domain of signal transducer and activator of transcription 3. J Med Chem 2011;54:3549-63
45. Turkson J, Gunning PT. 2-(9h-Purin-9-yl) Acetic acid analogues as inhibitors of STAT proteins: University of Central Florida Research Foundation, University of Toronto Mississauga. WO 163424 A2; 2011
46. Siddiquee K, Zhang S, Guidad WC, et al. Selective chemical probe inhibitor of STAT3, identified through structurebased virtual screening, induces antitumour activity. Proc Natl Acad Sci USA 2007;104:7391-6
47. Ojida A, Inoue M, Mito-oka Y, et al. Effective disruption of phosphoproteinprotein surface interaction using Zn(II) dipicolylamine-based artificial receptors via two-point interaction. J Am Chem Soc 2006;128:2052-8
48. Drewry JA, Fletcher S, Yue PB, et al. Coordination complex SH2 domain proteomimetics: an alternative approach to disrupting oncogenic protein-protein interactions. Chem Comm 2010;46:892-4
49. Zhao W, Jaganathan S, Turkson J. A cell-permeable STAT3 SH2 domain mimetic inhibits STAT3 activation and induces antitumour cell effects in vitro. J Biol Chem 2010;285:35855-65
50. Siddiquee KAZ, Gunning PT, Glenn M, et al. An Oxazole-based small-molecule STAT3 inhibitor modulates STAT3 stability and processing and induces antitumour cell effects. Chem Biol 2007;2:787-98
51. Turkson J, Hamilton AD, Jove R, Sebti SM. STAT3 inhibitor having anti-cancer activity and associated methods: University of Central Florida research foundation, Inc. WO 070697 A2; 2008
52. Turkson J, Hamilton AD, Jove R, Sebti SM. STAT3 Inhibitor Having Anti-Cancer Activity and Associated Methods. University of Central Florida Research Foundation Inc. EP 2120958 B1; 2013
53. Gunning PT, Glenn MP, Siddiquee KAZ, et al. Targeting proteinprotein interactions: suppression of STAT3 dimerization with rationally designed small-molecule, nonpeptidic SH2 domain binders. Chem Biol Chem 2008;9:2800-3
54. Turkson J, Jove R, Sebti SM, Hamilton AD. Peptidomimetic inhibitors of STAT Activity and uses thereof: university of south Florida. WO 073650 A2; 2004
55. Shahani VM, Yue P, Fletcher S, et al. Design, synthesis and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein. Bioorg Med Chem 2011;19:1823-38
56. Shahani VM, Yue PB, Haftchenary S, et al. Identification of purine-scaffold small-molecule inhibitors of STAT3 activation of QSAR studies. ACS Med Chem Letts 2011;2:79-84
57. Shahani VM, Ball DP, Ramos AV, et al. A 2,6,9-Hetero-trisubstituted purine inhibitor exhibits potent biological effects against multiple myeloma cells. Bioorg Med Chem 2013;21:5618-28
58. Turkson J, Sebti SM, Guida W, et al. Small-molecule inhibitors of STAT3 with antitumour activity: H. Lee Moffitt Cancer Center and Research Institute, University of Central Florida Research Foundation. US 7960434 B2; 2011
59. Fletcher S, Singh J, Zhang X, et al. Disruption of transcriptionally active STAT3 dimers with non-phosphorylated, salicylic acid-based small molecules: potent in vitro and tumour cell activities. Chem Bio Chem 2009;10:1959-64
60. Fletcher S, Page BDG, Zhang XL, et al. Antagonism of the STAT3-STAT3 protein dimer with salicylic acid-based small molecules. Chem Med Chem 2011;6:1459-70
61. Zhang XL, Yue PB, Fletcher S, et al. A novel small molecule disrupts STAT3 SH2 domain-phosphotyrosine interactions and stat3-dependent tumour processes. Biochem Pharm 2010;79:1398-409
62. Page BDG, Fletcher S, Yue PB, et al. Identification of a non-phosphorylated, cell-permeable, small-molecule ligand for the STAT3 SH2 domain. Bioorg Med Chem Letts 2011;21:5605-9
63. Gunning PT, Haftchenary S, Page BD, et al. New salicylic acid derivatives, pharmaceutically acceptable salt thereof and method of use thereof: the governing council of the university of Toronto. WO 177534 A2; 2013
64. Zhang XL, Yue PB, Page BDG, et al. Orally bioavailable small-molecule inhibitor of transcription factor STAT3 regresses human breast and lung cancer xenografts. Proc Nat Acad Sci USA 2012;109:9623-8.
65. Page BDG, Croucher DC, Li ZH, et al. Inhibiting aberrant signal transducer and activator of transcription protein activation with tetrapodal, small-molecule src homology 2 domain binders: promising agents against multiple myeloma. J Med Chem 2013;56:7190-200
66. Eiring AM, Page BDG, Kraft IL, et al. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia 2015;29:586-97
67. Haftchenary S, Luchman HA, Jouk AO, et al. Potent Targeting of the STAT3 Protein in Brain Cancer Stem Cells: A Promising Therapeutic Route for Treating Glioblastoma. ACS Med Chem Lett 2013;4:1102-7.
68. Sebti SM, Lawrence NJ, Lawrence HR. STAT3 dimerization inhibitors: h. Lee moffitt cancer center and research Institute. WO 070859 A1; 2014
69. Turkson J, Sebti SM, Guida W, et al. Small-Molecule Inhibitors of STAT3 with Antitumour Activity: H. Lee Moffitt Cancer Center and Research Institute, University of Central Florida Research Foundation. US 0069420 A1; 2009
70. Gao D, Hlinak AJ, Mazhary AM, et al. Celecoxib Compositions. Searle & Co. WO 032189 A1; 2000
71. Reed S, Li H, Li C, Lin J. Celecoxib inhibits STAT3 phosphorylation and suppresses cell migration and colonyforming ability in rhabdomyosarcoma cells. Biochem and Biophys Res Commun 2011;407:450-5
72. Daniels DJ, Parney IF, Peterson TE. Pyrazole derivatives as inhibitors of STAT3: Mayo Foundation for Medical Education and Research. WO 187965 A1; 2013
73. Asai A, Matsuno K, Ogo N, et al. STAT3 Inhibitor Containing Quinolinecarboxamide Derivative as Active Ingredient: Pharma. Ip. General, Inc. Mamoto Health Science University. EP 2325181 A1; 2011
74. Inaba M, Kobayashi T, Tashiro T, et al. Evaluation of antitumour activity in a human breast tumour/nude mouse model with a special emphasis on treatment dose. Cancer 1989;64:1577-82
75. Li P-K, Li C, Lin J, Fuchs JR. Curcumin analogs as dual JAK2/STAT3 Inhibitors and Methods of Making and Using the Same: The Ohio State University Research Foundation. US 0053208 A1; 2012
76. Dorland, Dorland's Illustrated Medical Dictionary, 2011
77. Haura EB, Zheng Z, Song L. Activated epidermal growth factor receptor-STAT3 signaling promotes tumour survival in vivo in non-small cell lung cancer. Clin Cancer Res 2005;11:8288-94
78. Halpern MS, England JM, Kopen GC, et al. Endogenous c-Src as a Determinant of the Tumourigenicity of Src Oncogenes. Proc Natl Acad Sci USA 1996;93:824-7
79. Allister AMC, Murone M, Sengupta S, Shetty SJ. Bicyclic compounds and their uses as dual c-Src/JAK Inhibitors: Debiopharm S. A., Aurigene Discovery Technologies LTD. WO 101806 A1; 2011
80. Sekiguchi K, Suzuki T, Ohbuchi Y, et al. STAT3/5 Activation Inhibitor: Otsuka Pharmaceutical Co., LTD. WO 044667 A1; 2008
81. Luu B, Mohier E, Yamada M. STAT3 Phosphorylation Inhibitor and Notch Expression Inhibitor: Meiji Dairies Corporation. US 0094061 A1; 2010
82. Weijzen S, Rizzo P, Braid M, et al. Activation of Notch-1 signaling maintains the neoplastic phenotype in human ras-transformed cells. Nat Med 2002;8:979-86
83. Jin S, Mutvei AP, Chivukula IV, et al. Non-canonical notch signaling activates IL-6/JAK/STAT signaling in breast tumour cells and is controlled by p53 and IKKa/IKKb. Oncogene 2013;41:4892-902
84. Hsu KW, Hsieh RH, Huang KH, et al. Activation of the Notch1/STAT3/Twist signaling axis promotes gastric cancer progression. Carcinogenesis 2012;33:1459-67
85. Li PK, Li C, Lin J. Transcription factor inhibitors and related compositions, formulations and methods: The Ohio University. US 0212911 A1; 2011
86. Lin L, Hutzen B, Li PK, et al. A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibts potent growth-suppressive activity in human cancer cells. Neoplasia 2010;12:39-50
87. Xu X, Qi W. One kind stat3 inhibitor-EGCG application of liver cancer treatment. 2012.CN103301111 A
88. Tan J, Luo D. Luteolin and diosmetin as novel STAT3 Inhibitors for Treating Autism: University of Florida. WO 062681 A2; 2010
89. Smith SEP, Li J, Garbett K, et al. Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci 2007;27:10695-701
90. Ogata A, Chauhan D, Teoh G, et al. IL-6 Triggers Cell Growth Via the Ras-Dependent Mitogen-Activated Protein Kinase Cascade. J Immunol 1997;159:2212-21
91. Yang EJ, Lee J, Lee SY, et al. EGCG attenuates autoimmune arthritis by inhibition of STAT3 and HIF-1a with Th17/Treg Control. PLoS One 2014;9:e86062-72
92. Agarwal C, Tyagi A, Kaur M, Agarwal R. Silibinin inhibits constitutive activation of STAT3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 Cells. Carcinogenesis 2007;28:1463-70
93. Gu M, Singh RP, Dhanalakshmi S. Silibinin inhibits inflammatory and angiogenic attributes in photocarcinogenesis in SKH-1 hairless mice. Cancer Res 2007;67:3483-91
94. Muthian G, Bright JJ, Quercetin A. Flavonoid Phytoestrogen, Ameliorates Experimental Allergic Encephalomyelitis by Blocking IL-12 Signaling Through JAK-STAT Pathway in T-Lymphocytes. J Clin Immunol 2004;24:542-52
95. Jiang Z, Li JC, Li W, Leggett D. Novel STAT3 Pathway Inhibitors and Cancer Stem Cell Inhibitors: Boston Biomedical Inc. WO 036059 A2; 2009
96. Kim MJ, Nam HJ, Kim HP, et al. OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett 2013;335:145-52
97. Hayakawa F, Sugimoto K, Harada Y, et al. A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases. Blood Cancer J 2013;3:UNSP e166
98. Brambilla L, Genini D, Laurini E, et al. Hitting the right spot: mechanism of action of OPB-31121, a novel and potent inhibitor of the signal transducer and activator of transcription 3 (STAT3). Mol Oncol 2015;9:1194-206
99. Phase I/II Study of OPB-31121 in Patients with Progressive Hepatocellular Carcinoma. US National Institute of Health. 2015. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01406574 [Last accessed 24 July 2015]
100. Nevalainen MT, Njar V, Liao Z, Reitz AB. Treatment of Prostate Cancer and Hematologic Neoplasms. In: Organization WIP Ed.: Thomas Jefferson University. WO 028080 A1; 2014
101. Jove R, Nam S, Skaltsounis AL. Indirubin Derivatives and Uses for Treating Chronic Myelogenous Leukemia: City of Hope, Durate, CA. US 0210834 A1; 2013
102. Swayze EE, Freier SM, Macleod RA, Kim Y. Modulation of Signal Transducer and Activator of Transcription 3 (STAT3) Expression: ISIS Pharmaceuticals, Inc. WO 135736 A2; 2012
103. Leong PL, Andrews GA, Johnson DE, et al. Targeting inhibition of STAT3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci USA 2003;7:4138-43
104. Grandis JR, Johnson DE, Leong P. STAT3 Decoy Oligonucleotides and Uses Thereof: University of Pittsburgh. WO 012625 A2; 2006
105. Xi S, Gooding WE, Grandis JR. In vivo antitumour efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene 2005;6:970-9
106. Zhang X, Zhang J, Wang L, et al. Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice. BMC Cancer 2007;7:149-59
107. Chan KS, Sano S, Kiguchi K, et al. Disruption of STAT3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest 2004;114:720-8
108. Shen J, Li R, Li G. Inhibitory effects of decoy-ODN targeting activated STAT3 on Human Glioma Growth In Vivo. 2009;23:237-43
109. Sen M, Tosca PJ, Zwayer C, et al. Lack of Toxicity of a STAT3 Decoy Oligonucleotide. Cancer Chemother. Pharmacol 2009;63:983-95
110. Sen M, Kim S, Yeh JI, et al. First-In-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumours: Implications for Cancer Therapy. Cancer Discovery 2012;8:694-705
111. Xie FY, Yanh X, Liu Y. Compositions Comprising STAT5 SiRNA and Methods of Use Thereof. Intradigm Corporation. WO 039199 A2; 2009
112. Drewry JA, Fletcher S, Yue PB, et al. Coordination complex SH2 domain proteomimetics: an alternative approach to disrupting oncogenic protein-protein interactions. Chem Comm 2010;46:892-4
113. Priebe W, Kato T, Fokt I, et al. Auranofin and Auranofin Analogs Useful to Treat Proliferative Disease and Disorders: Board regent, University of Texas System. WO 142615 A2; 2012
114. Sebti SM, Lawrence NJ, Turkson J. Platinum compounds that inhibit constitutive STAT3 signalling and induce cell cycle arrest and apoptosis of malignant cells. H. Lee Moffitt Cancer Center and Research Institute, Inc. University of Central Florida Research Foundation Inc. WO 063504 A1; 2013
115. Turkson J, Zhang S, Mora LB, et al. A novel platinum compound inhibits constitutive STAT3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J Biol Chem 2005;280:32979-88
116. Turkson J, Jove R, Sebti SM. Platinum IV complex inhibitor. H. Lee Moffitt Cancer Center and Research Institute. WO 071812 A2; 2006
117. Cumaraswamy AA, Lewis AM, Geletu M, et al. ACS Med Chem Lett 2014;5:1202-6
118. Elumalai N, Berg A, Natarajan K, et al. Nanomolar inhibitors of the transcriptional factor STAT5b with high selectivity over STAT5a. Angew Chem Int Ed 2015;54:4758-63